News

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced the completion of its arbitration1 with Merck Serono. The arbitral tribunal dismissed the majority of Merck...

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom...

PsiVac, a subsidiary of Ixogen; a UK biotechnology research and development company focused on the development of new therapeutic cancer treatments for solid tumors, and Lonza, a world leader in contract manufacturing, announced their agreement for the process development...

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it has expanded its previously-announced AdCOVID™ manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal...

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, announced that it is proud to be sponsoring RBQM Live on behalf of the industry. The adoption of Risk-Based Quality Management (RBQM)...

TrialScope, the global leader in clinical trial disclosure and transparency technology, recently added Alexion to its rapidly expanding roster of customers. Alexion joins the ranks of other industry leaders that rely on TrialScope Disclose™ to help manage global clinical trial...

Science 37, the industry leader in decentralized clinical trials, announced today a partnership with Xperiome, a global, rare disease healthtech company. The partnership further strengthens Science 37's capabilities to bring research directly to patients, easing patient's burden and enabling...